ScripAfter pulling back on M&A last year to digest the $43bn acquisition of Seagen in 2023, Pfizer said it is in a position to complete bigger deals this year, but that the company will be strategic ab
ScripScholar Rock, LLC unveiled Phase III data on 7 October that appears to make a strong case for its selective myostatin inhibitor apitegromab as additive therapy that can improve motor function in pati
ScripThe market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer
ScripBiohaven Ltd. is hoping it will have better luck this time around as it prepares to apply for US Food and Drug Administration approval of troriluzole in spinocerebellar ataxia (SCA) based on a real-w